Spruce Biosciences, Inc (SPRB) Kazanmak

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company is headquartered in South San Francisco, California and currently employs 8 full-time employees. The company went IPO on 2020-10-09. The firm has acquired an exclusive worldwide license agreement for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). The TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with modified human insulin-like growth factor 2 via an amino acid linker. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. The firm's pipeline also includes Tildacerfont and Cortibon for the treatment of Major Depressive Disorder, SPR202 for the treatment of Congenital Adrenal Hyperplasia and SPR204 for the treatment of Post-Bariatric Hypoglycemia.